SUBSCRIBE: Print / eNewsletter
Mastectomy Plus Reconstruction Has Highest Complication Rate
Among local treatment options for early breast cancer patients, mastectomy plus reconstruction has the highest rate of complications and is highest in cost.
Denosumab Benefits Postmenopausal Breast Cancer Patients
The addition of denosumab to adjuvant hormonal therapy in postmenopausal breast cancer patients improves disease-free survival compared with placebo.
Anthracyclines Negatively Impact Brain Function
Cancer survivors treated with anthracycline-based chemotherapies exhibited poorer performance of certain cognitive skills.
Survival Improvement in Women Presenting With Late-Stage Breast Cancer
Survival of women initially diagnosed with stage IV breast cancer has improved in the last 20 years, according to results of a retrospective cohort study.
Monitoring Lacking in Prostate Cancer Patients Choosing Surveillance
Men diagnosed with prostate cancer who opt for active surveillance/watchful waiting rather than active treatment may not be receiving quality monitoring of their disease.
Drop in PSA Screening Rates After USPSTF Recommendations
Following the USPSTF recommendation in 2012 against routine PSA screening, rates of screening and the incidence of early-stage prostate cancer have both declined.
False-Positive Mammograms Linked to Later Breast Cancer Risk
Women who previously had a false-positive mammogram or biopsy are at higher risk for developing breast cancer for at least 10 years, according to a new study.
NYC Program Diminishes Disparities, Sees Uptick in CRC Screening
A program implemented in New York City successfully increased colorectal cancer screening rates and diminished racial and ethnic disparities in screening.
FDA Approves Immunotherapy Nivolumab for Kidney Cancer
The FDA has approved the anti–PD-1 immunotherapy nivolumab (Opdivo) for the treatment of metastatic renal cell carcinoma.
Blood Draw Could Detect AI Resistance in Breast Cancer
Researchers have developed a blood-based assay that detects ESR1 mutations in circulating tumor DNA and could predict treatment failure in breast cancer patients.